Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer
Clinical trial NCT02215876 · WITHDRAWN
Trial details
- NCT number
- NCT02215876
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-01
- Primary completion
- 2017-08-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.